Bellevue Group’s West Pharmaceutical WST Stock Holding History

Bellevue Group’s Portfolio WST Stock Details WST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-520	Closed	-$171K	–	174
2024 Q2	$171K	Sell	520 -350	-40%	-$124K	﹤0.01%	152
2024 Q1	$344K	Buy	+870	New	+$322K	0.01%	141

Other funds holding WST

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

APG Asset Management Amsterdam, Netherlands $31.6B AUM 19.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bellevue Group's WST Position: Q3 2024 in Review

Bellevue Group sold out of West Pharmaceutical (WST) in Q3 2024, closing a stake of 520 shares — an estimated $171K sold.

Bellevue Group first reported a position in WST in Q1 2024 and held it in 2 quarters. The position peaked at $344K in Q1 2024. 729 funds tracked by Wall St. Rank hold WST as of Q3 2024.

Bellevue Group reported no remaining West Pharmaceutical position as of Q3 2024 after selling out during the quarter.
Bellevue Group sold 520 West Pharmaceutical shares in Q3 2024, an estimated $171K.
Bellevue Group first reported a position in West Pharmaceutical in Q1 2024 and held it in 2 quarters.
Bellevue Group's West Pharmaceutical position peaked at $344K in Q1 2024.
729 funds tracked by Wall St. Rank held West Pharmaceutical as of Q3 2024.

Based on Bellevue Group's 13F filing for Q3 2024, filed 14 Nov 2024.